a public good project by the
Synthesis
Company
of California

© 2026

Frank Behrens | doi.page

0 works0 citations0 h-index

Frank Behrens

Goethe University Frankfurt(DE)Fraunhofer Institute for Translational Medicine and Pharmacology(DE)University Hospital Frankfurt(DE)

Publications by Year

Research Areas

Rheumatoid Arthritis Research and Therapies, Psoriasis: Treatment and Pathogenesis, Spondyloarthritis Studies and Treatments, Autoimmune and Inflammatory Disorders Research, Systemic Lupus Erythematosus Research

Most-Cited Works

→ Correction: Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis(2015)862 cited
→ Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors(2017)505 cited
→ Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics(2013)504 cited
→ Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double‐blind, randomized, placebo‐controlled clinical trial(2004)411 cited
→ Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis(2010)365 cited
→ Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis(2021)289 cited

→ A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial(2019)283 cited

→ Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial(2020)278 cited

→ Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis(2022)194 cited

→ Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis(2015)184 cited